Rabbit anti-Human Complement Factor H (CFH) Polyclonal Antibody | anti-CFH antibody

Polyclonal Antibody to Complement Factor H (CFH)

Cat. Num. AAA2007161

• Gene Names: CFH; FH; HF; HF1; HF2; HUS; FHL1; AHUS1; AMBP1; ARMD4; ARMS1; CFHL3
• Reactivity: Human
• Applications: Immunocytochemistry, Immunohistochemistry, ELISA, Western Blot
• Purity: Affinity Chromatography
• Synonyms: Complement Factor H (CFH); Polyclonal Antibody; Polyclonal Antibody to Complement Factor H (CFH); anti-CFH antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Specificity: The antibody is a rabbit polyclonal antibody raised against CFH. It has been selected for its ability to recognize CFH in immunohistochemical staining andwestern blotting.
• Purity/Purification: Affinity Chromatography
• Form/Format: Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3,50% glycerol.
• Concentration: 500ug/mL (varies by lot)
• Sequence: Antigen: The target protein is fused with N-terminal His-Tag and its sequence is listed below.; MGHHHHHHSGSEF-S IPLCVEKIPC SQPPQIEHGT INSSRSSQES YAHGTKLSYT CEGGFRISEE NETTCYMGKW SSPPQCEGLP CKSPPEISHG VVAHMSDSYQ YGEEVTYKCF EGFGIDGPAI AKCLGEKWSH PPSCIKTDCL SLPSFENAIP MGEKKDVYKA GEQVTYTCAT YYKMDGASNV TCINSRWTGR PTCRDTSCVN PPTVQNAYIV SRQMSKYPSG ERVRYQCRSP YEMFGDEEVM CLNGNWTEPP QCKDSTGKCG PPPPIDNGDI TSFPLSVYAP ASSVEYQCQNLYQLEGNKRI TCRNGQWSEP PKCLHPCVIS REIMENYNIA LRWTAKQKLY SRTGESVEFV CKRGYRLSSR SHTLRTTCWD GKLEYPTCAK R
• Sequence Length: 449

• Applicable Applications for anti-CFH antibody: Immunocytochemistry (ICC), Immunohistochemistry (IHC) - Formalin/Paraffin, ELISA (EIA), Western Blot (WB)
• Application Notes: Western blotting: 1:100-400; Immunocytochemistry in formalin fixed cells: 1:100-500; Immunohistochemistry in formalin fixed frozen section: 1:100-500; Immunohistochemistry in paraffin section: 1:50-200; Enzyme-linked Immunosorbent Assay: 1:100-200
• Immunogen: Recombinant CFH (Ser860~Arg1231) expressed in E.coli.
• Cross Reactivity: Human
• Conjugated Antibody: The APC conjugated antibody version of this item is also available as catalog #MBS2045325
• Preparation and Storage: Store at 4 degree C for frequent use. Stored at -20 degree C to -80 degree C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Western Blot (WB)

(Western Blot: Sample: Lane1: Human Serum; Lane2: Human Liver Tissue.)

Western Blot (WB)

(Western Blot: Sample: Recombinant CFH, Human.)

Immunohistochemistry (IHC)

(DAB staining on IHC-P; Samples: Human Rectum Cancer Tissue.)

Immunohistochemistry (IHC)

(DAB staining on IHC-P; Samples: Human Skin Cancer Tissue)

Immunohistochemistry (IHC)

(DAB staining on IHC-P; Samples: Human Kidney Tissue)

NCBI and Uniprot Product Information

• NCBI GI #: 62739186
• NCBI GeneID: 3075
• NCBI Accession #: NP_000177.2
• NCBI GenBank Nucleotide #: NM_000186.3
• UniProt Accession #: P08603; P78435; Q14570; Q2TAZ5; Q38G77; Q5TFM3; Q8N708; Q9NU86; A5PL14
• Molecular Weight: 51,034 Da
• NCBI Official Full Name: complement factor H isoform a
• NCBI Official Synonym Full Names: complement factor H
• NCBI Official Symbol: CFH
• NCBI Official Synonym Symbols: FH; HF; HF1; HF2; HUS; FHL1; AHUS1; AMBP1; ARMD4; ARMS1; CFHL3
• NCBI Protein Information: complement factor H
• UniProt Protein Name: Complement factor H
• Protein Family: Complement factor
• UniProt Gene Name: CFH
• UniProt Synonym Gene Names: HF; HF1; HF2

NCBI Description

This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Oct 2011]

Uniprot Description

CFH: Factor H functions as a cofactor in the inactivation of C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement pathway. Genetic variations in CFH are associated with basal laminar drusen (BLD); also known as drusen of Bruch membrane or cuticular drusen or grouped early adult-onset drusen. Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. Basal laminar drusen refers to an early adult-onset drusen phenotype that shows a pattern of uniform small, slightly raised yellow subretinal nodules randomly scattered in the macula. In later stages, these drusen often become more numerous, with clustered groups of drusen scattered throughout the retina. In time these small basal laminar drusen may expand and ultimately lead to a serous pigment epithelial detachment of the macula that may result in vision loss. Defects in CFH are the cause of complement factor H deficiency (CFHD). A disorder that can manifest as several different phenotypes, including asymptomatic, recurrent bacterial infections, and renal failure. Laboratory features usually include decreased serum levels of factor H, complement component C3, and a decrease in other terminal complement components, indicating activation of the alternative complement pathway. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. Defects in CFH are a cause of susceptibility to hemolytic uremic syndrome atypical type 1 (AHUS1). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Genetic variation in CFH is associated with age-related macular degeneration type 4 (ARMD4). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid (known as drusen) that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 1q31.3

Cellular Component: extracellular region; extracellular space

Molecular Function: heparan sulfate proteoglycan binding; heparin binding; protein binding

Biological Process: complement activation; complement activation, alternative pathway; regulation of complement activation; viral process

Disease: Basal Laminar Drusen; Complement Factor H Deficiency; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 1; Macular Degeneration, Age-related, 4